A prospective study evaluating efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma

A prospective study evaluating efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma - efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031205

Enrollment

Registered

2018-03-21

Start date

2018-03-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper urinary tract urothelial carcinoma

Interventions

Administration of ALA HCl 2-4 hours before ureterorenoscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will undergo ureterorenoscopy for diagnosis of upper urinary tract urothelial carcinoma

Exclusion criteria

Exclusion criteria: Patients with allergy to ALA HCl or porphyrin, light hypersensitivity Patients with administration of the drugs which are contraindicated contraindication with ALA HCl Pregnant or lactating woman Patients with severe underlying diseases such as cardiovascular event, liver disfunction, diabetes mellitus, and so on. Patients who have been enrolled into another study.

Design outcomes

Primary

Measure	Time frame
Rates of pathologically positive patients who were photodynamically positive.	—

Countries

Japan

Contacts

Public ContactSatoshi Katayama

Okayama University Hospital Urology

skatayama18@gmail.com086-235-7287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026